A brief history of familial Mediterranean fever

Marwan H. Adwan, MRCPI, MSc.

Although familial periodic fever syndromes were described and identified in the latter half of the twentieth century, there have been descriptions of periodic fever since antiquity. In this short historical study, these milestones are briefly described starting with Galen and ending with the characterisation of the Mediterranean Fever (Mediterranean Fever (Mediterranean Fever) per se, or some other familial periodic fever syndrome is not certain. It is likely that they refer to FMF, since it is the most common of all the periodic fever syndromes. In the case described by Janeway and Mosenthal, the short duration of fever perhaps points to FMF instead of any other autoinflammatory syndrome.

The first accurate description of FMF was published in 1945 by Siegal who reported 10 cases of what he described as “at present little understood and often undiagnosed” under the name ‘benign paroxysmal peritonitis’. The syndrome since then, appeared under several other names including, periodic peritonitis, familial recurring polyserositis, Cattan-Mamou disease, Siegal-Cattan-Namou syndrome, and periodic disease. The latter term was coined by Reimann in 1948, who wrote “In naming them the adjectives periodic, cyclic, rhythmic, episodic, relapsing, paroxysmal, recurrent and intermittent are used interchangeably before the noun indicating the outstanding characteristic, as noted in the title and in the references”. Many other names appeared in the literature, including paroxysmal syndrome, Armenian disease, Periodic abdominalgia, La maladie périodique, La maladie dite périodique, La maladie de Siegal-Cattan-Mamou, La maladie périodique de Reimann, Periodic fever, Epanalepsie Mediterranéene and Recurrent polyserositis.

In 1951, 2 French physicians, Cattan & Mamou, noticed the association of FMF with renal disease. The occurrence of amyloidosis was reported 7 years later by Tuqan at the American University of Beirut in Lebanon. The actual modern name “familial Mediterranean fever” was coined by Heller et al in 1958, who emphasized the genetic nature of the disease. The exact etiology of the disease was unknown for a long time. However, the increased frequency in Arabs, Armenians, Jews, and Turks, and possible hereditary nature was noticed earlier. It was not until 1997 that the gene causing FMF (MEFV gene) was finally identified by positional cloning by 2 separate groups, American and French, and was mapped to chromosome 16. The gene product, a 781 amino acid protein, was named pyrin.
A brief history of familial Mediterranean fever ... Adwan

by the American group and marenostrin by the French group (Mare Nostrum: Latin for Mediterranean Sea). Since the identification of the MEFV gene in 1997, many studies, each involving up to a dozen or more investigators, were carried out by various groups around the world, all of whom broadened our understanding of this ancient disease at the molecular level. Listing each of these investigators is beyond the scope of this short historical study. To produce an inclusive list, one would have to include everyone who contributed to molecular biology since Watson and Crick and even beyond. However, I will briefly mention the most important advances.

The introduction of colchicine in 1972 as a prophylactic treatment in FMF has dramatically reduced the frequency of attacks as well as the incidence of the dreaded complication of amyloidosis. Despite its association with modernity, colchicine has been used for hundreds of years in an herbal form. In the early eleventh century Ibn Sina (Avicenna) described colchicum in the ‘Canon of medicine’ for the treatment of joint pains and gout. Ibn Sina perhaps did not know at that time how colchicine worked in relieving joint pains, but he knew that it did work. Eight centuries after Ibn Sina described colchicum, French chemists Pierre-Joseph Pelletier and Joseph Bienaimé Caventou isolated colchicine from the autumn crocus Colchicum autumnale, after which it was named in 1820. However, it was not until 1972 that colchicine was used prophylactically in FMF. Two years later, in 1974, the efficacy of colchicine was established through randomized controlled trials. In 1976, previous trials reported that colchicine works by inhibiting leukocyte migration, one and a half centuries after it was isolated. The discovery of a caspase-activating complex by Martinon et al in 2002, which they named “The Inflammasome”, provided the groundwork for unravelling the precise molecular mechanisms whereby pyrin participates in the disease process. Five years later in 2007, Papin et al in Switzerland showed that pyrin binds several components of the inflammasome, particularly caspase-1 and interleukin-1β. This was a breakthrough discovery that finally uncovered the precise disease process at the molecular level.

The discovery of MEFV gene and pyrin, marks a quantum leap in our understanding of nature of this interesting disease. Despite extensive study, the exact function of pyrin is not fully understood at present and the story of our understanding of the disease process and the potential institution of effective, and hopefully curative therapy, continues into the twenty-first century.

In conclusion, FMF is an ancient inherited periodic disease that had appeared in the literature under various names. Molecular characterization of the disease at the turn of the current century enormously expanded our understanding of the disease.

Received 23rd April 2015. Accepted 28th June 2015.

From the Department of Medicine, Division of Rheumatology, The University of Jordan, Amman, Jordan. Addressed correspondence to: Dr. Marwan H. Adwan, Department of Medicine, Division of Rheumatology, The University of Jordan, Amman, Jordan. E-mail: drm.adwan@yahoo.com

References

1. Reimann HA. Periodic disease. Medicine 1951; 30: 3.
2. Heberden W. Commentaries on history and care of disease. London (UK): Wells and Lilly; 1802. p. 151.
3. Osler W. On the visceral manifestations of erythema multiforme. Ann Med Sci 1895; 110: 629.
4. Janeway TC, Mosenthal HO. An unusual paroxysmal syndrome, probably allied to recurrent vomiting, with a study of the nitrogen metabolism. Arch Intern Med 1908; 2: 214-225.
5. Siegel S. Benign paroxysmal peritonitis. Ann Intern Med 1945; 23: 1-21.
6. Reimann HA. Periodic disease. JAMA 1948; 136: 239-244.
7. Reimann HA. Perplexities of a periodic entity. JAMA 1964; 190: 241.
8. Cattan R, Mamou H. [14 Cases of periodic disease, 8 of which are complicated by kidney diseases]. Bull Mem Soc Med Hop Paris 1951; 67: 1104-1107.
9. Tuqan NA. Periodic disease: a clinicopathologic study. Ann Intern Med 1958; 49: 885-899.
10. Heller H, Sohar E, Sherf L. Familial Mediterranean fever. AMJ Arch Intern Med 1958; 102: 50-71.
11. Daccak M. Periodic peritonitis, analysis of 19 cases. Diseases of the Colon & Rectum 1966; 9: 168-172.
12. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997; 90: 797-807.
13. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17: 25-31.
14. Hartung EF. History of the use of colchicum and related Medicaments in gout. Ann Rheum Dis 1954; 13: 190-200.
15. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972; 287: 1302.
16. Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, double-blind study. Ann Intern Med 1974; 81: 792-794.
17. Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med 1974; 291: 932-934.
18. Dinarello CA, Chusid MJ, Fauci AS, G blirin JI, Dale DC, Wolff SM. Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever. Arthritis Rheum 1976; 19: 618-622.
19. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417-426.
20. Papin S, Cuenin S, Agostini L, Martinon F, Werner S, Beer HD, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ 2007; 14: 1457-1466.